News articles about Amicus Therapeutics (NASDAQ:FOLD) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amicus Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.2589043942663 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- March 2nd Options Now Available For Amicus Therapeutics (FOLD) (nasdaq.com)
- Cowen Reaffirms “Buy” Rating for Amicus Therapeutics (FOLD) (americanbankingnews.com)
- Juniper Pharmaceuticals (JNP) versus Amicus Therapeutics (FOLD) Head-To-Head Survey (americanbankingnews.com)
- Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance (finance.yahoo.com)
- Amicus Therapeutics Sees Unusually Large Options Volume (FOLD) (americanbankingnews.com)
Several equities analysts have commented on the stock. BidaskClub cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Cowen reissued a “buy” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research report on Wednesday. Robert W. Baird reissued an “outperform” rating and issued a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Leerink Swann reissued a “buy” rating and issued a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Finally, Chardan Capital reissued a “buy” rating and issued a $18.50 price target (up previously from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $18.31.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. Amicus Therapeutics’s revenue for the quarter was up 419.0% on a year-over-year basis. During the same period last year, the firm posted ($0.33) earnings per share. sell-side analysts expect that Amicus Therapeutics will post -1.56 earnings per share for the current year.
In related news, SVP Daphne Quimi sold 8,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total value of $117,760.00. Following the completion of the sale, the senior vice president now directly owns 62,676 shares of the company’s stock, valued at $922,590.72. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO John F. Crowley sold 449,295 shares of the business’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the completion of the sale, the chief executive officer now directly owns 380,723 shares of the company’s stock, valued at $5,455,760.59. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 718,920 shares of company stock valued at $10,263,669. Corporate insiders own 3.40% of the company’s stock.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.